❌The Myth:
The Best Device Wins the Market!
Many medical device manufacturers operate on a simple assumption: if the device works better than what is currently on the market, it will succeed. Build the best robot, win the market. This belief is understandable. It reflects how most competitive industries function. In MedTech, it is dangerously incomplete.
✅The Reality:
Superior technical performance is a prerequisite for market success in MedTech, not a guarantee of it.
The assumption has roots in genuine market logic. Venture capital backs superior technology. R&D teams optimize for performance metrics. Clinical studies chase endpoints. Engineers and scientists rightly celebrate breakthroughs. The problem is not the innovation itself. The problem is the belief that regulatory, reimbursement, and market access considerations are secondary, something to address after the science is settled.
This sequencing is one of the most common and costly mistakes in MedTech.
What the Evidence Shows
Several well-documented cases illustrate the gap between technical superiority and commercial success in regulated markets.
Surgical Robotics: Capability Without Adoption
The surgical robotics sector is a striking example. Intuitive Surgical’s da Vinci system achieved dominant market share not primarily because it was the most technically advanced option at every moment, but because it secured early regulatory clearances, built a reimbursement pathway, and invested heavily in surgeon training and hospital integration. Subsequent entrants with comparable or superior capabilities faced the structural disadvantage of an entrenched installed base, established reimbursement codes, and trained user communities.
A 2022 analysis in the Journal of Medical Devices noted that market entry barriers in surgical robotics are now predominantly regulatory and economic, not technological. Competing on technical merit alone is insufficient when a competitor has already shaped the clinical workflow.
Source: Berguer R. et al. (2022). Market dynamics in surgical robotics: regulatory and reimbursement barriers to new entrants. Journal of Medical Devices, 16(2).
Diagnostics: The Regulatory Gap
In in vitro diagnostics, the transition from CE marking under the IVD Directive to the IVDR has created a striking divergence. Products that were clinically effective but had not invested in robust clinical evidence and quality management systems found themselves unable to secure market access under the new framework, regardless of their diagnostic performance.
The EU Commission’s own impact assessment acknowledged that a significant proportion of higher-risk IVDs on the European market had not been evaluated against clinical performance standards comparable to those now required under IVDR. Technical performance was real. Regulatory compliance was not.
Source: European Commission (2022). Report on the application of Regulation (EU) 2017/746 on in vitro diagnostic medical devices. COM/2022/0050.
Digital Health and SaMD: A New Frontier for the Same Problem
Software as a Medical Device (SaMD) developers frequently enter the market with technically sophisticated products and encounter regulatory frameworks they did not anticipate. FDA’s Digital Health Center of Excellence has published guidance on the Software Pre-Certification Programme and the evolving approach to AI and machine learning-based SaMD. The direction of travel is clear: clinical validation, transparency of algorithm behaviour, and post-market performance monitoring are becoming table stakes, not advanced requirements.
A 2023 report by the IMDRF noted that the majority of SaMD regulatory submissions globally lacked adequate clinical evidence at the time of first submission. Technical capability was present. Regulatory readiness was not.
Source: IMDRF (2023). Software as a Medical Device: Clinical Evaluation. IMDRF/SaMD WG/N41 FINAL.
The Three Gaps That Capability Alone Cannot Close
Technical superiority does not address the regulatory gap. Conformity assessment, clinical evidence requirements, and quality management system obligations exist independently of whether a device performs well in a laboratory. Regulators evaluate systems, not just outcomes.
Technical superiority does not address the reimbursement gap. In most markets, a device that lacks a reimbursement code or a Health Technology Assessment pathway will not reach patients at scale, regardless of its clinical value. HTA bodies in Germany (G-BA), France (HAS), and England (NICE) each apply their own evidence frameworks, and none of them defaults to approving a product because it is technically impressive.
Technical superiority does not address the adoption gap. Clinical workflows, procurement cycles, tender requirements, and institutional inertia all shape adoption. A device that requires significant behaviour change from clinicians faces implementation barriers that regulatory approval does not remove.
What EUMEDIQ Observes in Practice
Across the manufacturers EUMEDIQ works with, across the EU, UK, Switzerland, and beyond, the pattern is consistent. Companies that integrate regulatory strategy from early product development outperform those that treat compliance as a late-stage activity. This is not an opinion. It is visible in time-to-market data, in the cost of remediation work, and in the frequency of post-submission deficiency letters.
Regulatory intelligence is not bureaucratic overhead. It is a competitive input. Understanding what evidence regulators and payers will require, before committing to a clinical study design, shapes the efficiency of the entire development programme.
AIMEDIQ, EUMEDIQ’s AI-powered regulatory intelligence tool, supports this kind of early integration. It draws on a curated database of more than 1,800 controlled regulatory documents across FDA, EU MDR and IVDR, MHRA, Health Canada, TGA, PMDA, and other frameworks. It enables manufacturers to query regulatory requirements at the point in development when the answers still shape decisions, not after designs are locked.
Conclusion
The best device does not automatically win the market. The device that combines clinical performance with regulatory preparedness, reimbursement strategy, and market access planning is the one that reaches patients. In regulated markets, execution across all four dimensions is required. Technical excellence is necessary. It is not sufficient.
Bottom LineSuperior technical performance is a prerequisite for market success in MedTech, not a guarantee of it. Regulatory compliance, reimbursement pathways, and clinical adoption strategies each require equal investment. Manufacturers that treat these as sequential activities consistently face longer timelines and higher remediation costs than those who integrate them from the start. EUMEDIQ partners with manufacturers to close these gaps early. |
Interested in regulatory intelligence that supports your market access strategy? Explore AIMEDIQ or contact EUMEDIQ at www.eumediq.eu.